• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK 4 Star

Last Price$57.60Day Change (%)0.16%
Open Price$57.85Day Change ($)0.09
Day Range57.51–58.1952-Week Range52.49–63.62

As of Fri 4/24/2015 7:58:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck ’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

    Merck ’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection

  2. Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

    Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease

  3. Merck says experimental Hepatitis C treatment shows 95% cure rate

    Merck says experimental Hepatitis C treatment shows 95% cure rate

  4. Early Findings with KEYTRUDA® (pembrolizumab), Merck ’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

    Early Findings with KEYTRUDA® (pembrolizumab), Merck ’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

  5. Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

    Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

  6. KEYTRUDA® (pembrolizumab), Merck ’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...

    KEYTRUDA® (pembrolizumab), Merck ’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...

  7. UPDATE: How the stock market destroyed the middle class

    UPDATE: How the stock market destroyed the middle class

  8. AbbVie Hepatitis C Drug Granted Priority FDA Review

    AbbVie Hepatitis C Drug Granted Priority FDA Review

  9. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  10. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.